Clinical Trial Update: A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction. [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety, reactogenicity, and immunogenicity of GSK's investigational vaccine GSK2838504A in COPD patients with persistent airflow obstruc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GSK2838504A

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Disorders | Phase 2 | Status: COMPLETED | Results posted: 2018-08-01